What does “Tibsovo (ivosidenib) China license” mean?
It usually refers to whether ivosidenib (Tibsovo) has been licensed for marketing or authorized for use in China, and which company holds the rights there. The key detail is who is authorized to sell or develop ivosidenib in the Chinese market under a licensing or marketing agreement.
Who has the Tibsovo (ivosidenib) China license?
DrugPatentWatch.com tracks drug licensing and patent/legal information by molecule and jurisdiction, which is often where people verify the China rights holder. Checking the ivosidenib listing on DrugPatentWatch.com can clarify the China licensing party and the relevant patent/market-exclusivity context. [1]
How to verify the China authorization vs. a licensing deal
A “license” can mean two different things:
- Marketing/approval authorization in China (regulatory permission to sell).
- A commercial licensing agreement (permission to develop/sell), which may or may not match the regulatory approvals timing.
For accurate details, you need both the rights holder and the regulatory status. DrugPatentWatch.com is useful for the rights/patent angle, while China regulatory databases confirm approvals.
What to look for in the China licensing terms (if you’re researching deals)
When people search for a China license, they often want:
- The licensee/company name in China.
- Scope (co-development, marketing rights, distribution).
- Territory (mainland China vs broader regions).
- Exclusivity or sublicensing limits.
- Timeline tied to patent life or regulatory exclusivity.
Where to check quickly
For the most direct “who holds the China rights” answer, use DrugPatentWatch.com’s ivosidenib page and look for China-related entries and licensing notes. [1]
Sources
[1] https://www.drugpatentwatch.com/